Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Preliminary Revenue Exceeding Guidance for the Fourth Quarter and Full Year 2021
Fourth quarter preliminary revenue of $38.0 to $38.3 million Full year 2021 preliminary revenue of $130.3 to $130.6 million Base product and service revenue growth of approximately 13% for fourth quarter and 12% for full year as new Biomark OEM and CyTOF XT instruments  contributed to revenue SOUTH
View HTML
Toggle Summary Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company’s Biomark Platform Detects Omicron Variant of COVID-19
No Published Viral Mutations to Date, Including Omicron Variant, Meaningfully Impact the Regions of the Viral Genome Targeted by the Assay SOUTH SAN FRANCISCO, Calif. , Dec. 07, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
View HTML
Toggle Summary Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite , President and CEO, and Vikram Jog, Chief
View HTML
Toggle Summary Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost
Streamlines Operations to Reduce Hands-On Time, Accelerate Results Broad Menu of Applications with Automated Workflow Providing Sample-to-Answer Solutions on a Single Platform SOUTH SAN FRANCISCO, Calif. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative
View HTML
Toggle Summary Fluidigm Announces Third Quarter 2021 Financial Results
Board Undertaking Review of Range of Value-Enhancing Opportunities SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced
View HTML
Toggle Summary Imaging Mass Cytometry Utilized to Seek Molecular Links between African Ancestry and Aggressive Forms of Breast and Prostate Cancer
IMC Studies Part of New York Genome Center’s Polyethnic-1000 Initiative Advancing Understanding of Racial Disparities in the Prevalence of Cancer Types SOUTH SAN FRANCISCO, Calif. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results
SOUTH SAN FRANCISCO, Calif. , Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday,
View HTML
Toggle Summary Fluidigm 2021 IMC Summit Focuses on ‘Uncovering Spatial Biology’
Latest Imaging Mass Cytometry Discoveries in Infectious Disease, Immuno-Oncology and the Tumor Microenvironment from Expert Users of the Technology SOUTH SAN FRANCISCO, Calif. , Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a
View HTML
Toggle Summary Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software
Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers SOUTH SAN FRANCISCO, Calif. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life
View HTML
Toggle Summary Fluidigm Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT
Department of Women’s and Children’s Health to Work with Fluidigm on CyTOF Research Applications, Product Development SOUTH SAN FRANCISCO, Calif. , Sept. 28, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML